Bayer taps a second partner to develop Vitrakvi's companion diagnostic

Six months into Vitrakvi larotrectinib's approval as a tissue-agnostic therapy, Bayer has added a second co-development partnership for the NTRK inhibitor's still-needed companion diagnostic, this time with Roche's Foundation Medicine unit.

In April 2018, Vitrakvi's

Read the full 344 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE